Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience.
Identifieur interne : 005186 ( PubMed/Curation ); précédent : 005185; suivant : 005187Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience.
Auteurs : S L Blethen [États-Unis] ; D B Allen ; D. Graves ; G. August ; T. Moshang ; R. RosenfeldSource :
- The Journal of clinical endocrinology and metabolism [ 0021-972X ] ; 1996.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Enfant, Femelle, Gynécomastie (), Hormone de croissance (déficit), Hormone de croissance (effets indésirables), Hormone de croissance (usage thérapeutique), Humains, Leucémies (), Lymphoedème (), Mâle, Naevus (anatomopathologie), Oedème (), Protéines recombinantes (effets indésirables), Protéines recombinantes (usage thérapeutique), Récidive, Syndrome d'hypertension intracrânienne bénigne (), Syndrome du canal carpien (), Tumeurs ().
- MESH :
- anatomopathologie : Naevus.
- déficit : Hormone de croissance.
- effets indésirables : Hormone de croissance, Protéines recombinantes.
- usage thérapeutique : Hormone de croissance, Protéines recombinantes.
- Adolescent, Adulte, Enfant, Femelle, Gynécomastie, Humains, Leucémies, Lymphoedème, Mâle, Oedème, Récidive, Syndrome d'hypertension intracrânienne bénigne, Syndrome du canal carpien, Tumeurs.
English descriptors
- KwdEn :
- Adolescent, Adult, Carpal Tunnel Syndrome (chemically induced), Child, Edema (chemically induced), Female, Growth Hormone (adverse effects), Growth Hormone (deficiency), Growth Hormone (therapeutic use), Gynecomastia (chemically induced), Humans, Leukemia (chemically induced), Lymphedema (chemically induced), Male, Neoplasms (chemically induced), Nevus (pathology), Pseudotumor Cerebri (chemically induced), Recombinant Proteins (adverse effects), Recombinant Proteins (therapeutic use), Recurrence.
- MESH :
- chemical , adverse effects : Growth Hormone, Recombinant Proteins.
- chemically induced : Carpal Tunnel Syndrome, Edema, Gynecomastia, Leukemia, Lymphedema, Neoplasms, Pseudotumor Cerebri.
- chemical , deficiency : Growth Hormone.
- pathology : Nevus.
- chemical , therapeutic use : Growth Hormone, Recombinant Proteins.
- Adolescent, Adult, Child, Female, Humans, Male, Recurrence.
Abstract
The National Cooperative Growth Study has monitored the safety of recombinant human GH (rhGH) since 1985. Data have been collected from more than 19,000 children representing over 47,000 patient-years of rhGH treatment. Children receiving GH for renal disease were more likely to develop problems such as intracranial hypertension than those with GH deficiency (P < 0.01). Children with idiopathic short stature were less likely to develop slipped capital femoral epiphysis than those with GH deficiency or Turner's syndrome (P < 0.01). There was no evidence of an increased recurrence of leukemia or central nervous system tumors. There were 3 new cases of leukemia in children without known risk factors for developing leukemia and 5 cases in children with known risk factors. Growth deceleration associated with high affinity, high capacity antibodies to GH was found in only 2 of 5039 subjects tested (0.04%). Major adverse events in association with rhGH treatment have been rare, and preexisting medical conditions such as renal insufficiency may affect their frequency.
DOI: 10.1210/jcem.81.5.8626820
PubMed: 8626820
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005186
Links to Exploration step
pubmed:8626820Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience.</title><author><name sortKey="Blethen, S L" sort="Blethen, S L" uniqKey="Blethen S" first="S L" last="Blethen">S L Blethen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, State University of New York, Stony Brook 11794-8111, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatrics, State University of New York, Stony Brook 11794-8111</wicri:regionArea></affiliation></author><author><name sortKey="Allen, D B" sort="Allen, D B" uniqKey="Allen D" first="D B" last="Allen">D B Allen</name></author><author><name sortKey="Graves, D" sort="Graves, D" uniqKey="Graves D" first="D" last="Graves">D. Graves</name></author><author><name sortKey="August, G" sort="August, G" uniqKey="August G" first="G" last="August">G. August</name></author><author><name sortKey="Moshang, T" sort="Moshang, T" uniqKey="Moshang T" first="T" last="Moshang">T. Moshang</name></author><author><name sortKey="Rosenfeld, R" sort="Rosenfeld, R" uniqKey="Rosenfeld R" first="R" last="Rosenfeld">R. Rosenfeld</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1996">1996</date><idno type="RBID">pubmed:8626820</idno><idno type="pmid">8626820</idno><idno type="doi">10.1210/jcem.81.5.8626820</idno><idno type="wicri:Area/PubMed/Corpus">005186</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005186</idno><idno type="wicri:Area/PubMed/Curation">005186</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005186</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience.</title><author><name sortKey="Blethen, S L" sort="Blethen, S L" uniqKey="Blethen S" first="S L" last="Blethen">S L Blethen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, State University of New York, Stony Brook 11794-8111, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatrics, State University of New York, Stony Brook 11794-8111</wicri:regionArea></affiliation></author><author><name sortKey="Allen, D B" sort="Allen, D B" uniqKey="Allen D" first="D B" last="Allen">D B Allen</name></author><author><name sortKey="Graves, D" sort="Graves, D" uniqKey="Graves D" first="D" last="Graves">D. Graves</name></author><author><name sortKey="August, G" sort="August, G" uniqKey="August G" first="G" last="August">G. August</name></author><author><name sortKey="Moshang, T" sort="Moshang, T" uniqKey="Moshang T" first="T" last="Moshang">T. Moshang</name></author><author><name sortKey="Rosenfeld, R" sort="Rosenfeld, R" uniqKey="Rosenfeld R" first="R" last="Rosenfeld">R. Rosenfeld</name></author></analytic><series><title level="j">The Journal of clinical endocrinology and metabolism</title><idno type="ISSN">0021-972X</idno><imprint><date when="1996" type="published">1996</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Carpal Tunnel Syndrome (chemically induced)</term><term>Child</term><term>Edema (chemically induced)</term><term>Female</term><term>Growth Hormone (adverse effects)</term><term>Growth Hormone (deficiency)</term><term>Growth Hormone (therapeutic use)</term><term>Gynecomastia (chemically induced)</term><term>Humans</term><term>Leukemia (chemically induced)</term><term>Lymphedema (chemically induced)</term><term>Male</term><term>Neoplasms (chemically induced)</term><term>Nevus (pathology)</term><term>Pseudotumor Cerebri (chemically induced)</term><term>Recombinant Proteins (adverse effects)</term><term>Recombinant Proteins (therapeutic use)</term><term>Recurrence</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Enfant</term><term>Femelle</term><term>Gynécomastie ()</term><term>Hormone de croissance (déficit)</term><term>Hormone de croissance (effets indésirables)</term><term>Hormone de croissance (usage thérapeutique)</term><term>Humains</term><term>Leucémies ()</term><term>Lymphoedème ()</term><term>Mâle</term><term>Naevus (anatomopathologie)</term><term>Oedème ()</term><term>Protéines recombinantes (effets indésirables)</term><term>Protéines recombinantes (usage thérapeutique)</term><term>Récidive</term><term>Syndrome d'hypertension intracrânienne bénigne ()</term><term>Syndrome du canal carpien ()</term><term>Tumeurs ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Growth Hormone</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Naevus</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Carpal Tunnel Syndrome</term><term>Edema</term><term>Gynecomastia</term><term>Leukemia</term><term>Lymphedema</term><term>Neoplasms</term><term>Pseudotumor Cerebri</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Growth Hormone</term></keywords><keywords scheme="MESH" qualifier="déficit" xml:lang="fr"><term>Hormone de croissance</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hormone de croissance</term><term>Protéines recombinantes</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Nevus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Growth Hormone</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hormone de croissance</term><term>Protéines recombinantes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Child</term><term>Female</term><term>Humans</term><term>Male</term><term>Recurrence</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Enfant</term><term>Femelle</term><term>Gynécomastie</term><term>Humains</term><term>Leucémies</term><term>Lymphoedème</term><term>Mâle</term><term>Oedème</term><term>Récidive</term><term>Syndrome d'hypertension intracrânienne bénigne</term><term>Syndrome du canal carpien</term><term>Tumeurs</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The National Cooperative Growth Study has monitored the safety of recombinant human GH (rhGH) since 1985. Data have been collected from more than 19,000 children representing over 47,000 patient-years of rhGH treatment. Children receiving GH for renal disease were more likely to develop problems such as intracranial hypertension than those with GH deficiency (P < 0.01). Children with idiopathic short stature were less likely to develop slipped capital femoral epiphysis than those with GH deficiency or Turner's syndrome (P < 0.01). There was no evidence of an increased recurrence of leukemia or central nervous system tumors. There were 3 new cases of leukemia in children without known risk factors for developing leukemia and 5 cases in children with known risk factors. Growth deceleration associated with high affinity, high capacity antibodies to GH was found in only 2 of 5039 subjects tested (0.04%). Major adverse events in association with rhGH treatment have been rare, and preexisting medical conditions such as renal insufficiency may affect their frequency.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8626820</PMID><DateCreated><Year>1996</Year><Month>06</Month><Day>21</Day></DateCreated><DateCompleted><Year>1996</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-972X</ISSN><JournalIssue CitedMedium="Print"><Volume>81</Volume><Issue>5</Issue><PubDate><Year>1996</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of clinical endocrinology and metabolism</Title><ISOAbbreviation>J. Clin. Endocrinol. Metab.</ISOAbbreviation></Journal><ArticleTitle>Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience.</ArticleTitle><Pagination><MedlinePgn>1704-10</MedlinePgn></Pagination><Abstract><AbstractText>The National Cooperative Growth Study has monitored the safety of recombinant human GH (rhGH) since 1985. Data have been collected from more than 19,000 children representing over 47,000 patient-years of rhGH treatment. Children receiving GH for renal disease were more likely to develop problems such as intracranial hypertension than those with GH deficiency (P < 0.01). Children with idiopathic short stature were less likely to develop slipped capital femoral epiphysis than those with GH deficiency or Turner's syndrome (P < 0.01). There was no evidence of an increased recurrence of leukemia or central nervous system tumors. There were 3 new cases of leukemia in children without known risk factors for developing leukemia and 5 cases in children with known risk factors. Growth deceleration associated with high affinity, high capacity antibodies to GH was found in only 2 of 5039 subjects tested (0.04%). Major adverse events in association with rhGH treatment have been rare, and preexisting medical conditions such as renal insufficiency may affect their frequency.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blethen</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, State University of New York, Stony Brook 11794-8111, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>D B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Graves</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>August</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Moshang</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Rosenfeld</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Endocrinol Metab</MedlineTA><NlmUniqueID>0375362</NlmUniqueID><ISSNLinking>0021-972X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-72-6</RegistryNumber><NameOfSubstance UI="D013006">Growth Hormone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002349" MajorTopicYN="N">Carpal Tunnel Syndrome</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013006" MajorTopicYN="N">Growth Hormone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006177" MajorTopicYN="N">Gynecomastia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007938" MajorTopicYN="N">Leukemia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009506" MajorTopicYN="N">Nevus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011559" MajorTopicYN="N">Pseudotumor Cerebri</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8626820</ArticleId><ArticleId IdType="doi">10.1210/jcem.81.5.8626820</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005186 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 005186 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:8626820
|texte= Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:8626820" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |